User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.30 1.5% 155.30 156.20 156.40 157.60 153.00 153.00 652,256 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 473.2 -126.5 -14.6 - 1,140

Indivior Share Discussion Threads

Showing 3526 to 3545 of 3750 messages
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
DateSubjectAuthorDiscuss
16/10/2020
00:38
15 October 2020 Indivior to Announce 2020 Year-to-Date and Q3 Results October 29th Slough, UK, and Richmond, VA, 15 October 2020 - Indivior PLC (LON: INDV) today announced that it will release its 2020 year-to-date and third quarter results on Thursday, October 29th at 11:00 London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the Company's website at www.indivior.com . Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 London time (8:00 a.m. U.S. Eastern) on October 29th. Access the Live Results Webcast October 29th The webcast event will be available on the "Investors" section of the Company's website at www.indivior.com . The webcast link is hxxps://edge.media-server.com/mmc/p/py8oqyrx . Participants also may access the results presentation telephonically: US participants +1-646-741-3167; international participants +44 (0) 2071-928338. Please reference confirmation number 6570529. A replay of the presentation will be available at www.indivior.com . About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
waldron
15/10/2020
15:17
standard life must be down to 5 per cent
timmy11
15/10/2020
14:38
Buvidal is the one currently being trialed. Sublocade is waiting on final government approval. We understand Sublocade will have different dose sizes and there may be other small differences, but they are essentially the same drug taken the same way.4 Jul 2019 FROM 4TH JULY 2019
timmy11
15/10/2020
11:02
lets see how far they want to bring down the share price before they buy again
timmy11
15/10/2020
11:01
standard life manipulating market
timmy11
06/10/2020
11:24
http://uk.advfn.com/stock-market/london/indivior-INDV/share-news/Indivior-PLC-Holdings-in-Company/83403233 A REDUCTION IN HOLDING
grupo
30/9/2020
14:25
who was affected and will they get recompense pally
grupo
26/9/2020
07:22
Https://www.pharmaceutical-technology.com/news/indivior-restructuring-expenses-70m/ The company also plans on developing its early-stage pipeline assets, including INDV-2000 for treating opioid use disorder and INDV-1000 for alcohol use disorder treatment.
adrian j boris
24/9/2020
11:33
Indivior Reorganises Amid Challenges; Still In Line With Expectations Thu, 24th Sep 2020 10:44 (Alliance News) - Indivior PLC on Thursday said it is taking organisational and cost actions amid the challenges posed by the Covid-19 pandemic. Indivior is a US-based pharmaceutical company focused on the treatment of opioid addiction and mental illnesses. Indivior expects to reduce its operating expense base by between USD60.0 million to USD70.0 million pre-tax in 2021 compared with its expected operating expense base in 2020, the company said. A restructuring charge of approximately USD6.0 million to pay for this will be booked as an exceptional item in the third quarter of 2020. Indivior says the restructuring involves reorganizing and reinvesting in the US commercial function, focusing on research & development on post-marketing studies to support its Subcolade and Perseris products, the former used to treat opioid addiction and the latter used to treat schizophrenia. Finally, the company will focus on the development of early-stage pipeline assets. Indivior says business performance during the third quarter has been in-line with the financial year's planning assumptions, with the exception that its Suboxone Film, a prescription medicine used to treat opioid addiction. This has continued to perform ahead of expectations. Indivior shares were up 5.9% at 122.60 pence each on Thursday morning in London. By Greg Roxburgh; gregroxburgh@alliancenews.com
the grumpy old men
24/9/2020
09:54
Oliver Haill 09:00 Thu 24 Sep 2020 Indivior cutting jobs as part of product refocus Within the pipeline, the priorities include a potential treatment of alcohol use disorder Suboxone sales are not declining as expected Indivior PLC (LON:INDV) said it is cutting jobs and reducing discretionary spending to save money as its further shifts its emphasis away from its Suboxone Film anti-opioid-addiction product. The reorganisation will see a shift towards the US sales functions to focus on the 'organised health system' for its Sublocade monthly anti-opioid-addiction injection and its Perseris treatment for the treatment of schizophrenia. READ: Indivior soars as it reaches settlement with US authorities over Suboxone lawsuit This includes hiring and redirecting some employees from other parts of the business. Group performance during the third quarter has been in-line with the 'planning assumptions' given at its interim results in July, apart from Suboxone performing better than expected. The company, which was spun out of Reckitt Benckiser in 2014, said it was also going to focus more research & development on “post-marketing studies” to support these two products, as well as on its early-stage pipeline assets. Within the pipeline, the priorities are INDV-2000, another potential treatment for opioid use disorder, and INDV-1000, a potential treatment of alcohol use disorder. As well as streamlining certain corporate functions, reduced discretionary spending will include suspending bonus increases and lowering third-party expenditure. Indivior, which has operations in Slough, England and Richmond, Virginia, USA, expects to cut its cost base by US$60-70mln in 2021. Chief executive Mark Crossley said: “We are taking the right strategic actions on organizational focus and cost management to better align our capabilities and resources with the group's near- and medium-term priorities, while also supporting our long-term growth ambitions.” Proactiveinvestors
the grumpy old men
24/9/2020
09:40
Michele Maatouk Sharecast News 24 Sep, 2020 09:23 24 Sep, 2020 09:25 Indivior to axe jobs, restructure as it looks to cut costs Opioid addiction treatment maker Indivior outlined plans on Thursday to reduce costs through job cuts and restructuring, as it looks to support long-term growth ambitions and protect its financial and operational flexibility in response to the pandemic. The company said it will reorganise and reinvest in the US commercial function in-line with the continued penetration and growth of Sublocade. It will also focus research and development on post-marketing studies to support Sublocade and Perseris. Indivior said it will be "streamlining" certain corporate functions and reducing discretionary spending, including suspending merit-based pay rises and lowering third-party expenditures. Based on these measures, it expects to cut its operating expense base by between $60m and $70m pre-tax in 2021. The company said its third-quarter performance has been in-line with the expectations outlined at the end of July, with the exception that Suboxone Film share has continued to perform ahead of historical industry analogues and group expectations. Chief executive officer Mark Crossley said: "We are taking the right strategic actions on organisational focus and cost management to better align our capabilities and resources with the group’s near- and medium-term priorities, while also supporting our long-term growth ambitions. "While some of the expected savings will be reinvested to support the continued growth of Sublocade and Perseris in the US and targeted international geographies, we will retain a large portion of the expected savings to preserve the group’s flexibility through the Covid-19 pandemic. In addition, we are maintaining our core capabilities in addiction science to support drug discovery and development." As far as jobs are concerned, Crossley said that while some teams will remain unchanged, others will be reduced "to align with our strategic priorities".
the grumpy old men
24/9/2020
08:52
RNS Number : 9398Z Indivior PLC 24 September 2020 Indivior Takes Strategic Alignment Actions This release contains inside information. Slough, United Kingdom and Richmond, Virginia - September 24, 2020 - Indivior PLC (LON: INDV) today announced that it is taking organizational and cost actions to better align its capabilities and resources with the Group's strategic priorities. These actions further consider Indivior's strategy and are intended to enhance the Group's commercial and R&D focus on the highest value opportunities, protect the Group's financial and operational flexibility in response to ongoing challenges posed by the COVID-19 pandemic and support the Group's long-term growth ambitions. Key actions Indivior is taking include: -- Reorganizing and reinvesting in the U.S. commercial function in-line with the continued penetration and growth of SUBLOCADE (R) (buprenorphine extended-release) Injection in the Organized Health System (OHS) channel and to facilitate expansion of PERSERIS (R) (risperidone) extended release injection into the OHS channel. This includes hiring and redirecting some employees to further our progress in this channel. -- Further focusing of R&D on post-marketing studies to support SUBLOCADE(R) and PERSERIS(R) and on the development of early-stage pipeline assets with the prioritization of INDV-2000 (selective Orexin-1 receptor antagonist) for the treatment of opioid use disorder and INDV-1000 (selective GABAb positive allosteric modulator) for the treatment of alcohol use disorder . -- Streamlining certain corporate functions and reducing discretionary spending, including suspending merit-based pay increases and lowering third-party expenditures. Comment by Mark Crossley, CEO of Indivior PLC: "We are taking the right strategic actions on organizational focus and cost management to better align our capabilities and resources with the Group's near- and medium-term priorities, while also supporting our long-term growth ambitions. While some of the expected savings will be reinvested to support the continued growth of SUBLOCADE(R) and PERSERIS(R) in the U.S. and targeted international geographies, we will retain a large portion of the expected savings to preserve the Group's flexibility through the COVID-19 pandemic. In addition, we are maintaining our core capabilities in addiction science to support drug discovery and development. These actions will result in a stronger organization with an improved cost position and the ability to continue to make investments to strengthen the global delivery platforms for SUBLOCADE(R) and PERSERIS(R). Critically, we are maintaining our strong commitment to integrity and compliance." "These actions, unfortunately, will impact our workforce as we are reorganizing and reallocating healthcare practitioner-facing resources in the U.S. toward Organized Health Systems, streamlining certain corporate functions and reducing discretionary expenses. While some teams will remain unchanged, others will be reduced in size to align with our strategic priorities. As always, we will look to support those that will be departing the Group." Based on the actions set out above, Indivior expects to reduce its operating expense base (SG&A plus R&D) by between $60m to $70m pre-tax in 2021 compared with its expected operating expense base in 2020 on an adjusted basis, excluding exceptional items. For reference, Indivior's H1 2020 adjusted operating expenses were $242m and the Group's FY 2020 Planning Assumptions include a slightly lower level of operating expenses on an adjusted basis in H2 2020 compared with H1 2020. A restructuring charge of approximately $6m will be booked as an exceptional item in the Q3 2020 financial results (which are scheduled to be reported on October 29, 2020). Actions associated with the key elements of the program are expected to be completed in the fourth quarter of 2020. Indivior notes that business performance during the third quarter of 2020 has been in-line with the FY 2020 Planning Assumptions it outlined on July 30(th) as part of its H1 2020 results announcement, with the exception that SUBOXONE(R) Film share has continued to perform ahead of historical industry analogues (1) and Group expectations. (1) IMS Institute Report, January 2016, "Price Declines after Branded Medicines Lose Exclusivity in the U.S."
the grumpy old men
24/9/2020
08:49
Indivior notes that business performance during the third quarter of 2020 has been in-line with the FY 2020 Planning Assumptions it outlined on July 30th as part of its H1 2020 results announcement, with the exception that SUBOXONE® Film share has continued to perform ahead of historical industry analogues (1) and Group expectations.
steeplejack
21/9/2020
19:41
Https://www.marketscreener.com/quote/stock/INDIVIOR-PLC-19356217/ NOW THATS A REAL JUMP BUT WHY INDIVIOR PLC (INVVY) Delayed Quote. Delayed OTC Bulletin Board - Other OTC - 09/21 07:26:46 pm 10.88 USD +37.20%
maywillow
21/9/2020
09:21
Upcoming events on INDIVIOR October/29/2020 Q3 2020 Earnings Release
waldron
21/9/2020
08:50
Price (GBX) 115.90 -4.69% (-5.70) Open / Last close 122.70 / 121.60 High / Low 124.60 / 115.80 Bid / Offer 115.90 / 116.30 Special Condition: - Trading Status: Regular Trading FTSE All-Share As at 21.09.20 08:33:05 - All data delayed at least 15 minutes
grupo
20/9/2020
12:17
Https://www.law360.com/articles/1311656/wholesaler-fights-to-stay-suboxone-product-hop-class-rep Https://eu.democratandchronicle.com/story/news/2020/03/12/rdc-declares-bankruptcy-aftermath-opioid-prosecution/5030036002/
waldron
09/9/2020
12:37
Longer term INDV holders can make demands for governance reforms and seek restitution on behalf of the company, for the failures in corporate governance the lead to the guilty pleas and $600 million fines. Cash incentives are typically awarded to the demanding shareholder(s) as well. Another side of investing when these situations arise. Feel free to message me here to learn more. https://grabarlaw.com/current-investigations/indivior-investigation/
jgrabar
09/9/2020
12:31
It's the electric chair for him then.......
meijiman
05/9/2020
18:15
RNS Number : 1399Y Indivior PLC 04 September 2020 September 4, 2020 Indivior PLC - Board Announcement Indivior PLC announces that the Chair of the Board, Howard Pien, who has been on a medical leave since June 15, 2020, has notified the Board of his resignation with immediate effect. Daniel Tassé, who was appointed as Interim Chair in Mr Pien's absence, will continue to act as Interim Chair until the Board appoints Mr Pien's successor. The Board will commence a process to identify a successor. Mr Tasse joined the Board in 2014 and was appointed Senior Independent Director in 2016 ( bio ). He is a member of the Audit and Remuneration Committees.
grupo
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210509 04:31:20